425

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2008

EBIX, INC.
(Exact name of registrant as specified in its charter)

Delaware	0-15946	77-0021975
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5 Concourse Parkway, Suite 3200, Atlanta, Georgia	30328
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (678) 281-2020

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

þ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01: Other Events.

On October 30, 2008, the registrant, Ebix, Inc. (NASDAQ: EBIX), announced via a press release that it had issued a number of clarifications regarding its recently released final firm, time bound, all stock offer at $0.85 per share in respect to a business combination transaction with HealthAxis, Inc. (“HealthAxis”) (NASDAQ: HAXS).  Ebix (or the “Company), in response to quires received from HeathAxis’s investment relations group and its shareholders, determined that it was best interest of the HealthAxis shareholders and the Company to provide these clarifications in a public manner.

A copy of this press release is attached as Exhibit 99.1 and is incorporated herein by reference. A copy of Ebix’s letter to the HealthAxis board of directors is attached as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01: Exhibits.

The following exhibits are being furnished with this report pursuant to Item 8.01of this Form 8-K:

Exhibit No.	Description
99.1	Press Release dated October 30, 2008 re: Ebix’s Firm, Time Bound Offer to Purchase Healthaxis.
99.2	Letter dated October 30, 2008 from Ebix to HealthAxis’s Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EBIX, INC.

By: /s/ Robert F. Kerris                          
Robert Kerris
Chief Financial Officer
and Corporate Secretary

October 30, 2008

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated October 30, 2008 re: Ebix’s Firm, Time Bound Offer to Purchase Healthaxis.
99.2	Letter dated October 30, 2008 from Ebix to HealthAxis’s Board of Directors.

EX-99.1

Exhibit 99.1

EBIX ISSUES CLARIFICATIONS ON ITS LAST 85 CENTS OFFER

ATLANTA, GA – October 30, 2008 – Ebix, Inc. (NASDAQ: EBIX), a leading international developer and supplier of software and e-commerce solutions to the insurance industry, today issued a number of clarifications regarding its last 85 cents offer sent to the Healthaxis Board of Directors. Ebix decided to issue these clarifications in a public manner, in response to queries received by its Investment Relations group, from Healthaxis shareholders over the last few days.

Ebix confirmed the following:

1. Registered and Unrestricted stock: Ebix confirmed that it intends to provide registered, unrestricted Ebix stock to the Healthaxis shareholders, while getting the merger approved by the SEC through a S-4 filing, as mandated in the present Healthaxis-BPOM agreement (section 7.3)

2. Termination fee to BPOM: Ebix confirmed that it will pay the increased termination fee of $1 million in termination fees to BPOM, in case Healthaxis merges with Ebix

3. Binding agreement within 7 days: Ebix confirmed that it will serve a binding agreement for the acquisition of Healthaxis within 7 days of acceptance of the above offer.

4. Waiver of Due Diligence Rights: Ebix has not been provided detailed due diligence rights by the Healthaxis Board. In spite of that, Ebix agrees to waive is right to due diligence, to convey its seriousness and readiness to close the transaction in an expeditious manner.

5. Future Direction: In case Ebix’s offer is declined again by the Healthaxis Board, Ebix intends to undertake a detailed review of all options available to it and then make its intentions public.

The above clarifications to its previous offer were outlined in a new letter sent by Robin Raina, Chairman and Chief Executive Officer of Ebix Inc., to the Healthaxis Board of Directors today.

About Ebix

Ebix, Inc. is a leading international supplier of software and e-commerce solutions to the insurance industry. Ebix provides a series of application software products for the insurance industry ranging from carrier systems, agency systems and exchanges to custom software development for all entities involved in the insurance and financial services industries.

Ebix strives to work collaboratively with clients to develop innovative technology strategies and solutions that address specific business challenges. Ebix combines the newest technologies with its capabilities in consulting, systems design and integration, IT and business process outsourcing, applications software, and Web and application hosting to meet the individual needs of organizations.

With bases in Singapore, Australia, the US, UK, New Zealand, India and Canada, Ebix employs insurance and technology professionals who provide products, support and consultancy to more than 3,000 customers on six continents. Ebix’s focus on quality has enabled it be awarded Level 5 status of the Carnegie Mellon Software Engineering Institute’s Capability Maturity Model (CMM). Ebix has also earned ISO 9001:2000 certification for both its development and call center units in India. For more information, visit the Company’s website at www.ebix.com

Safe Harbor for Forward Looking Statements under the Private Securities Litigation Reform Act of 1995 — This press release contains various forward-looking statements and information that are based on Ebix management’s beliefs, as well as assumptions made by and information currently available to management. Ebix has tried to identify such forward looking statements by use of such words as “will,” “expects,” “intends,” “anticipates,” “plans,” “believes” and similar expressions, but these words are not the exclusive means of identifying such statements. Such statements are subject to various risks, uncertainties and other factors which could cause actual results to vary materially from those expressed in, or implied by, the forward looking statements. Such risks, uncertainties and other factors include the extent to which the Ebix.com website and other new products and services can be successfully developed and marketed, the risks associated with any future acquisitions, and integrating recently completed acquisitions, the willingness of independent insurance agencies to outsource their computer and other processing needs to third parties, possible governmental regulation and/or other adverse consequences resulting from negative perception of the outsourcing of business processes to foreign countries, Ebix’s ability to continue to develop new products to effectively address market needs in an industry characterized by rapid technological change, Ebix’s ability to raise additional capital to finance future acquisitions and meet other funding needs, Ebix’s dependence on a few customers(including one that is Ebix’s largest stockholder), Ebix’s dependence on the insurance industry, the highly competitive and rapidly changing automation systems market, Ebix’s ability to effectively protect its applications software and other proprietary information, Ebix’s ability to attract and retain quality management, and software, technical sales and other personnel, the risks of disruption of Ebix’s Internet connections or internal service problems, the possible adverse effects of a substantial increase in volume of traffic on Ebix’s website, mainframe and other servers, possible security breaches on the Ebix website, the possible effects of insurance regulation on Ebix, the possible effects of the Securities and Exchange Commission’s investigation of Ebix’s financial reporting, and possible future terrorist attacks or acts of war. Certain of these, as well as other risks, uncertainties and other factors, are described in more detail in Ebix’s periodic filings with the Securities and Exchange Commission, including Ebix’s quarterly report on Form 10-K for the year ended December 31, 2007. Except as expressly required by the federal securities laws, Ebix undertakes no obligation to update any such factors or any of the forward-looking statements contained herein to reflect changed circumstances or future events or developments or for any other reason.

Contacts:
Jesenia Jurado
678-281-2036 or ir@ebix.com

EX-99.2

Exhibit 99.2

October 30, 2008

Board of Directors
C/o John Carradine
HealthAxis Inc.
7301 State Hwy 161
Suite 300
Irving, TX 75039

Dear Members of the Board:

Subsequent to our previous offer, we would like to confirm the following:

1. Registered and Unrestricted stock: Ebix confirmed that it intends to provide registered, unrestricted Ebix stock to the Healthaxis shareholders, while getting the merger approved by the SEC through a S-4 filing, as mandated in the present Healthaxis-BPOM agreement (section 7.3)

2. Termination fee to BPOM: Ebix confirmed that it will pay the increased termination fee of $1 million in termination fees to BPOM, in case Healthaxis merges with Ebix

3. Binding agreement within 7 days: Ebix confirmed that it will serve a binding agreement for the acquisition of Healthaxis within 7 days of acceptance of the above offer.

4. Waiver of Due Diligence Rights: Ebix has not been provided detailed due diligence rights by the Healthaxis Board. In spite of that, Ebix agrees to waive is right to due diligence, to convey its seriousness and readiness to close the transaction in an expeditious manner.

5. Future Direction: In case Ebix’s offer is declined again by the Healthaxis Board, Ebix intends to undertake a detailed review of all options available to it and then make its intentions public.

We look forward to hearing from you.

Sincerely,

/s/ Robin Raina                                       
Robin Raina
President & CEO